Search results

128 results

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Social care guidelines Remove Social care guidelines filter
Public health guidelines Remove Public health guidelines filter
Interventional procedures guidance Remove Interventional procedures guidance filter

Setmelanotide for treating obesity caused by LEPR or POMC deficiency [ID3764]

Proposed [GID-HST10034] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
VTS-270 for treating Niemann-Pick type C1 (ID1267)

Proposed [GID-HST10020] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223

Proposed [GID-HST10019] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]

Proposed [GID-HST10037] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Avalglucosidase alfa for treating Pompe disease [ID3737]

Proposed [GID-HST10030] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Lonafarnib for treating progeria and progeroid laminopathies [ID3867]

Proposed [GID-HST10039] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

Proposed [GID-HST10022] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Maralixibat for treating type 2 progressive familial intrahepatic cholestasis ID3818

Proposed [GID-HST10040] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Lenti-D for treating cerebral adrenoleukodystrophy [ID1284]

Proposed [GID-HST10038] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

Proposed
Bupivacaine–meloxicam for treating postoperative pain [ID2728]

Proposed [GID-TA10716] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mepolizumab for treating hypereosinophilic syndrome [ID3749]

Proposed [GID-TA10755] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Sotagliflozin for treating type 2 diabetes [ID1657]

Proposed [GID-TA10665] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Slow-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis [ID3787]

Proposed [GID-TA10753] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]

Proposed [GID-TA10668] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]

Proposed [GID-TA10637] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]

Proposed [GID-TA10638] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)

Proposed [GID-TA10279] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tocilizumab for treating systemic sclerosis (ID1396)

Proposed [GID-TA10346] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Intravenous zanamivir for treating influenza in hospital [ID1196]

Proposed [GID-TA10298] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700]

Proposed [GID-TA10574] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]

Proposed [GID-TA10599] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]

Proposed [GID-TA10604] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]

Proposed [GID-TA10667] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [ID2690]

Proposed [GID-TA10666] Expected publication date: 26 August 2021

Type

Technology appraisal guidance

Status

Proposed
Oleogel-S10 for treating skin wounds associated with epidermolysis bullosa [ID1505]

Proposed [GID-TA10654] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Diroximel fumarate for treating relapsing-remitting multiple sclerosis [ID1673]

Proposed [GID-TA10714] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]

Proposed [GID-TA10727] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]

Proposed [GID-TA10728] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Amivantamab for non-small cell lung cancer [ID3836]

Proposed [GID-TA10729] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
177Lu-PSMA-617 for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]

Proposed [GID-TA10730] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]

Proposed [GID-TA10700] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cabotegravir and rilpivirine for treating HIV-1 [ID3766]

Proposed [GID-TA10658] Expected publication date: 20 October 2021

Type

Technology appraisal guidance

Status

Proposed
Aducanumab for treating mild cognitive impairment in early Alzheimer's disease [ID3763]

Proposed [GID-TA10739] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tofacitinib for treating juvenile idiopathic arthritis [ID2718]

Proposed [GID-TA10706] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]

Proposed [GID-TA10722] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]

Proposed [GID-TA10598] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1581]

Proposed [GID-TA10740] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Selumetinib for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over [ID1590]

Proposed [GID-TA10535] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]

Proposed [GID-TA10685] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Filgotinib for treating moderately to severely active ulcerative colitis [ID3736]

Proposed [GID-TA10600] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers [ID3837]

Proposed [GID-TA10737] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Avatrombopag for treating chronic immune thrombocytopenia [ID3838]

Proposed [GID-TA10738] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Ozanimod for treating moderate to severe ulcerative colitis [ID3841]

Proposed [GID-TA10732] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Upadacitinib for treating active ankylosing spondylitis [ID3848]

Proposed [GID-TA10735] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

Proposed [GID-TA10332] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154

Proposed [GID-TA10198] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

Proposed [GID-TA10336] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)

Proposed [GID-TA10426] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Voxelotor for treating sickle cell disease [ID1403]

Proposed [GID-TA10505] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Semaglutide for treating type 2 diabetes (ID1450)

Proposed [GID-TA10438] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed